Advance online publication

The latest articles published online ahead of print. These online versions are definitive and may be cited using the digital object identifier (DOI).


25 July 2017

Research Highlights

Gastrointestinal cancer: Establishing a family tree | PDF (183 KB)

Published online: 25 July 2017 | doi:10.1038/nrclinonc.2017.115

Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease | PDF (159 KB)

Published online: 25 July 2017 | doi:10.1038/nrclinonc.2017.119



The immune contexture in cancer prognosis and treatment

Wolf H. Fridman, Laurence Zitvogel, Catherine Sautès–Fridman & Guido Kroemer

Published online: 25 July 2017 | doi:10.1038/nrclinonc.2017.101

Virtually all successful treatments of cancer either create, restore or enhance the antitumour immune response. Therefore, the specific features of the immune microenvironment, both before and after treatment, are important determinants of patients' outcomes. In this Review, the authors describe the influence of the immunological characteristics of the tumour microenvironment on responses to treatment in patients with a variety of cancers.


18 July 2017

Research Highlights

Prevention: Low-fat diet linked to decline in breast cancer mortality | PDF (77 KB)

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.110

Breast cancer: Profiling of ultra-low-risk disease | PDF (81 KB)

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.114

Immunotherapy: Reality check for nivolumab in advanced-stage melanoma | PDF (85 KB)

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.112

Prostate cancer: Mutations in ctDNA reflect features of metastatic disease | PDF (83 KB)

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.111


News and Views

Health policy: Me-too drugs with limited benefits — the tale of regorafenib for HCC

Bishal Gyawali & Vinay Prasad

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.100

Regorafenib is only the second agent approved by the FDA for the treatment of patients with advanced-stage hepatocellular carcinoma. Herein, we discuss the evidence that led to the approval of this agent. Examination of this process reveals important challenges associated with drug regulation, relating to trial design, treatment toxicity, and real-world clinical benefit.

Outcomes research: Integrating PROs into the clinic — overall survival benefit or not, it's worth the trouble

Elisa Sperti & Massimo Di Maio

Published online: 18 July 2017 | doi:10.1038/nrclinonc.2017.109

In 2016, results of an important randomized trial demonstrated that patients undergoing chemotherapy who reported symptoms electronically have a better quality of life than those receiving usual care. Now, a significant survival improvement for patients in the experimental arm of this study has been reported. The emphasis of this survival benefit is 'culturally' positive, promoting the adoption of patient-reported outcomes in clinical practice.


11 July 2017

Research Highlights

In brief

Genetics: BRCA-mutant breast/ovarian cancer revealed | PDF (81 KB)

Published online: 11 July 2017 | doi:10.1038/nrclinonc.2017.104

Targeted therapy: ctDNA identified in patients with CUP | PDF (81 KB)

Published online: 11 July 2017 | doi:10.1038/nrclinonc.2017.105

Melanoma: Neadjuvant BRAF inhibition enables resection | PDF (81 KB)

Published online: 11 July 2017 | doi:10.1038/nrclinonc.2017.106

Haematological cancer: Low-dose CAR T cells are safe and effective | PDF (81 KB)

Published online: 11 July 2017 | doi:10.1038/nrclinonc.2017.107


04 July 2017


Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells

Hui K. Gan, Martin van den Bent, Andrew B. Lassman, David A. Reardon & Andrew M. Scott

Published online: 04 July 2017 | doi:10.1038/nrclinonc.2017.95

Few therapeutic options are currently available for patients with glioblastoma, which are associated with a poor prognosis. Therapies with monoclonal antibodies, alone or linked to cytotoxic payloads, are currently being explored in these patients. Herein, the authors summarize therapeutic strategies based on antibody–drug conjugates (ADCs), targeted against EGFR, and discuss key aspects such as the blood–brain barrier, resistance mechanisms, and the development of specific biomarkers.

Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary

Sebastián Moran, Anna Martinez-Cardús, Stergios Boussios & Manel Esteller

Published online: 04 July 2017 | doi:10.1038/nrclinonc.2017.97

The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings. Epigenetic and other molecularly-based diagnostic strategies have emerged to complement traditional diagnostic procedures, thereby improving the clinical management of patients with CUP. Herein, the authors present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, addressing a previously unmet need.


27 June 2017


Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Mizuki Nishino, Nikhil H. Ramaiya, Hiroto Hatabu & F. Stephen Hodi

Published online: 27 June 2017 | doi:10.1038/nrclinonc.2017.88

Patients receiving anticancer therapies based on immune-checkpoint blockade (ICB) often experience clinical benefits from such treatments, but unconventional patterns of response can be observed, emphasizing the importance of using a specific approach to evaluating responses to immunotherapy. Herein, the authors review the biological mechanisms underlying the response patterns associated with ICB, describe strategies for the assessments of such responses, and highlight the ongoing efforts to identify biomarkers to guide treatment with ICB.


20 June 2017

News and Views

Haematological cancer: Staging and restaging patients with lymphoma — a better approach?

Vijaya R. Bhatt & James O. Armitage

Published online: 20 June 2017 | doi:10.1038/nrclinonc.2017.81

Response criteria for disease assessment have important therapeutic and prognostic implications in clinical trials and in routine clinical practice. The Lugano classification has been used widely for evaluation of the response of patients with lymphoma to treatment, although the alternative Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) classification was recently proposed; these criteria are compared herein.


13 June 2017



Evolution of lymphoma staging and response evaluation: current limitations and future directions

Joel Cunningham, Sunil Iyengar & Bhupinder Sharma

Published online: 13 June 2017 | doi:10.1038/nrclinonc.2017.78

Accurate detection and monitoring of treatment responses is an essential element of the management of patients with lymphoma. In this Perspectives, the authors describe the evolution of lymphoma staging criteria and highlight unaddressed questions, which, if answered, will substantially improve the management of patients with lymphoma.


31 May 2017


Clinical utility of gene-expression signatures in early stage breast cancer

Maryann Kwa, Andreas Makris & Francisco J. Esteva

Published online: 31 May 2017 | doi:10.1038/nrclinonc.2017.74

Patients with early stage breast cancer have traditionally been assigned adjuvant systemic therapies on the basis of the clinical and histological characteristics of their disease. However, this approach often leads to overtreatment. In this Review, the authors describe the use of gene-expression signatures, some of which are already in clinical use, for determining the risks of recurrence and progression, and the most appropriate form of adjuvant therapy.


23 May 2017


Unravelling the biology of SCLC: implications for therapy

Joshua K. Sabari, Benjamin H. Lok, James H. Laird, John T. Poirier & Charles M. Rudin

Published online: 23 May 2017 | doi:10.1038/nrclinonc.2017.71

For three decades, the treatment of small-cell lung cancer (SCLC) has remained essentially unchanged, and patient outcomes remain dismal. In the past 5 years, however, advances in our understanding of the disease, at the molecular level, have resulted in the development of new therapeutic strategies, encompassing immunotherapies and novel molecularly targeted agents. Herein, authors review the breakthroughs that hold the promise to improve SCLC outcomes.



Combining drugs and extending treatment — a PFS end point is not sufficient

Published online: 23 May 2017 | doi:10.1038/nrclinonc.2017.72


11 April 2017


EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

Tsukasa Shibue & Robert A. Weinberg

Published online: 11 April 2017 | doi:10.1038/nrclinonc.2017.44

According to the cancer stem cell (CSC) paradigm, a minor subpopulation of cancer cells with stem-cell properties predominantly underlies tumour progression, therapy resistance, and disease recurrence. Notably, epithelial-to-mesenchymal transition (EMT) is implicated in these processes, and CSCs typically show markers of EMT-programme activation. Herein, the authors outline our current understanding of the links between the EMT programme, the CSC phenotype, metastasis, and drug resistance, and discuss the potential for therapeutic targeting of these facets of tumour biology.


04 April 2017


Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

Conor A. Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero, Hajrah A. Khawaja, Mark Lawler, Patrick G. Johnston, Sandra Van Schaeybroeck & on behalf of the MErCuRIC consortium

Published online: 04 April 2017 | doi:10.1038/nrclinonc.2017.40

Patients with c-MET-expressing colorectal or gastrointestinal cancers generally have worse outcomes than those of patients whose tumours have low levels of, or absent c-MET expression. However, c-MET targeted agents have, thus far, failed to show clinical efficacy. In this Review, the authors describe the opportunities and challenges created by the clinical implementation of c-MET targeted therapies.


02 March 2017


Integrating liquid biopsies into the management of cancer

Giulia Siravegna, Silvia Marsoni, Salvatore Siena & Alberto Bardelli

Published online: 02 March 2017 | doi:10.1038/nrclinonc.2017.14

Analysis of circulating tumour components using liquid biopsy approaches holds considerable promise to improve the detection and treatment of cancer. In this Review, Alberto Bardelli and colleagues outline how different forms of liquid biopsy, and particularly the assessment of circulating tumour DNA, can be exploited to guide patient care, and discuss the progress made to date in integrating such analyses into the clinic.


14 February 2017



The changing landscape of clinical trial and approval processes in China

Qing Zhou, Xiao-Yuan Chen, Zhi-Min Yang & Yi-Long Wu

Published online: 14 February 2017 | doi:10.1038/nrclinonc.2017.10

The expansion of research and development of anticancer drugs in China has resulted in considerable delays in the approval of both clinical trials of novel agents, and the marketing approval of these agents once tested. In this Perspective, the authors describe the measures taken by the Chinese FDA to address these challenges in a rapidly developing research environment.


About AOP

Until print versions of AOP papers are published, they should be cited in the style "Nature Reviews Clinical Oncology AOP, published online day month year; doi:10.1038/nrclinoncXXX". Once the print version (identical to the AOP) is published, it should be cited as follows: "Nature Reviews Clinical Oncology volume number, page range (year); doi:10.1038/nrclinoncXXX".

Extra navigation


Subscribe to Nature Reviews Clinical Oncology